ZNTL Zentalis Pharmaceuticals Inc

Price (delayed)

$2.87

Market cap

$205.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.95

Enterprise value

$211.85M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 9

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of ...

Highlights
The revenue has surged by 100% year-on-year
ZNTL's gross profit has soared by 100% YoY
Zentalis Pharmaceuticals's EPS has increased by 14% YoY but it has decreased by 13% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 14% YoY but it has decreased by 12% from the previous quarter
ZNTL's equity is down by 48% YoY and by 21% from the previous quarter
Zentalis Pharmaceuticals's quick ratio has decreased by 40% YoY and by 23% from the previous quarter

Key stats

What are the main financial stats of ZNTL

ZNTL stock price

How has the Zentalis Pharmaceuticals stock price performed over time
Intraday
-6.82%
1 week
-7.42%
1 month
-24.97%
1 year
91.33%
YTD
112.59%
QTD
-40.82%

Financial performance

How have Zentalis Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$153.37M
Net income
-$139.55M
Gross margin
N/A
Net margin
N/A
The revenue has surged by 100% year-on-year
ZNTL's gross profit has soared by 100% YoY
The operating income has grown by 39% YoY but it has contracted by 6% from the previous quarter
Zentalis Pharmaceuticals's net income has increased by 14% YoY but it has decreased by 12% from the previous quarter

Price vs fundamentals

How does ZNTL's price correlate with its fundamentals

Growth

What is Zentalis Pharmaceuticals's growth rate over time

Valuation

What is Zentalis Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Zentalis Pharmaceuticals's EPS has increased by 14% YoY but it has decreased by 13% from the previous quarter
The P/B is 53% more than the last 4 quarters average of 1.0 but 43% less than the 5-year quarterly average of 2.7
ZNTL's equity is down by 48% YoY and by 21% from the previous quarter
The revenue has surged by 100% year-on-year

Efficiency

How efficient is Zentalis Pharmaceuticals business performance
The ROE has declined by 36% year-on-year and by 31% since the previous quarter
The ROA is down by 28% year-on-year and by 27% since the previous quarter
ZNTL's ROIC is down by 28% year-on-year and by 28% since the previous quarter

Dividends

What is ZNTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZNTL.

Financial health

How did Zentalis Pharmaceuticals financials performed over time
Zentalis Pharmaceuticals's quick ratio has decreased by 40% YoY and by 23% from the previous quarter
The current ratio has decreased by 40% YoY and by 22% from the previous quarter
The company's debt is 77% lower than its equity
The debt to equity has surged by 64% year-on-year and by 21% since the previous quarter
ZNTL's equity is down by 48% YoY and by 21% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.